Princy Daniel, NP
Family · New York, NYNPI 1184189292
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 395 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Johnson & Johnson at 38.2% of the total. 2025 is the largest year on record at $3,131, 3.7 times the $851 reported in 2021. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 395 payments — averaging $24.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Pfizer$582
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$485
- Lilly USA, LLC$392
- plus $1K from 12 others
What the payments were for
- Food & beverage$9,47898%
- Education$2402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 130 | $3,717 |
| AbbVie | 84 | $1,879 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $1,200 |
| Pfizer | 24 | $582 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $485 |
| Lilly USA, LLC | 24 | $392 |
| Merck | 13 | $272 |
| QOL Medical, LLC | 7 | $270 |
| Boehringer Ingelheim | 8 | $212 |
| Celltrion USA Inc. | 8 | $185 |
| Daiichi Sankyo Inc. | 6 | $134 |
| Bristol Myers Squibb | 5 | $113 |
| Aimmune Therapeutics, Inc. | 4 | $90 |
| Integra Lifesciences Corporation | 2 | $71 |
| Janssen Scientific Affairs, LLC | 2 | $51 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Organon | 1 | $24 |
| Redhill Biopharma Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,718 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 52 | $1,409,128 |
| GattexTeduglutide | 11 | $501,999 |
| Humira(Cf) PenAdalimumab | 14 | $211,082 |
| EntyvioVedolizumab | 20 | $168,973 |
| RinvoqUpadacitinib | 12 | $73,943 |
| Mesalamine | 20 | $4,468 |
| Mesalamine ErMesalamine | 13 | $2,448 |
| Omeprazole | 19 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $3,717 | $1,409,12852 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex, Entyvio | $1,200 | $670,97231 claims |
| AbbVieRinvoq | $1,879 | $73,94312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in New York
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Mary Sullivan-WhalenNew York$137K
- Leslie WoronaNew York$77K
- Thomas SaglimbeniNew York$48K
- Kathryn JohnsonNew York$48K
- Derek PinedaNew York$38K
- Rebecca SchoriNew York$32K
- Evangelia NezisNew York$22K
- Colette NelsonNew York$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.